China-based SciBrunch Therapeutics has closed an oversubscribed Pre-A series financing round of over USD 35 million. This latest funding, combined with an angel round completed in June 2025, brings the company's total capital raised within a year to USD 65 million. The proceeds will accelerate the clinical development of its lead asset and advance preclinical programs.

The funds are allocated to advance the core candidate, SPR1020, a next-generation, brain-penetrant PARP1 inhibitor, which recently dosed its first patient in a clinical trial. The capital will also support investigational new drug (IND)-enabling studies for a novel molecular glue-type RAS inhibitor, targeting RAS-mutant refractory cancers such as colorectal (CRC), pancreatic and non-small cell lung cancer (NSCLC). The company focuses on developing differentiated small molecule oncology therapies with best-in-class potential.

According to PharmCube's NextBiopharm® database, the company's pipeline additionally has two preclinical candidates for solid tumours. Click here to request a free trial for NextBiopharm®.